Key highlights
- Novo Nordisk and OpenAI will apply advanced AI across drug discovery, manufacturing, supply chain and commercial operations.
- Pilot programmes will run across R&D, manufacturing and commercial operations, with full integration by end of 2026.
- Partnership includes global workforce upskilling and improved AI literacy.
- Use is structured with strict data protection, governance and human oversight for ethical, compliant deployment.
Partnership scope
Novo Nordisk has entered a strategic partnership with OpenAI to apply advanced AI across drug discovery, manufacturing, supply chain, distribution and commercial operations, aiming to analyse complex datasets, identify drug candidates and shorten research-to-patient timelines.
Workforce and operations
OpenAI will assist in upskilling Novo Nordisk’s global workforce and improving AI literacy; pilot programmes will run across R&D, manufacturing and commercial operations to test applications and drive efficiency in production, supply chain and corporate functions.
Governance and timeline
The collaboration includes measures for data protection, governance and human oversight to promote ethical, compliant AI use; pilots are launching now with full integration targeted by the end of 2026.
